Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* KRAS and NRAS wild type metastatic colorectal cancer~* Progression following treatment for colorectal cancer with irinotecan, oxaliplatin and fluoropyrimidine therapy in the metastatic setting.~* Eastern Cooperative Oncology Group \[ECOG\] Performance Status of 0, 1, or 2~* At least one measurable lesion by Response Evaluation Criterion in Solid Tumors \[RECIST\]~Exclusion Criteria:~* More than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer.~* Prior treatment with a PI3K, mTOR, AKT or EGFR inhibitor~* Patients who have discontinued treatment with prior irinotecan therapy due to toxicity.~* Prior radiation to the pelvis or abdomen~* Patients with history of interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): PF-05212384 plus Irinotecan
- Arm B (Type: ACTIVE_COMPARATOR): Cetuximab plus Irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).